CD105 in the Progression and Therapy of Colon Cell Carcinoma

Preview this chapter:

CD105 in the Progression and Therapy of Colon Cell Carcinoma, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815305906/chapter-3-1.gif

Colon cell carcinoma (CRC) poses a significant global health challenge, demanding thorough exploration. This chapter meticulously navigates the multifaceted landscape of CRC, elucidating its definition, prevalence, and established risk factors. The spotlight then shifts to CD105, an enigmatic glycoprotein intricately woven into the fabric of CRC progression. CD105 emerges as a key player in orchestrating tumor hallmarks, influencing angiogenesis, cell proliferation, invasion, and immune evasion. Discussions unfold on its clinical significance, serving as a diagnostic, prognostic, and predictive marker. Case studies illustrate CD105's pivotal role in guiding clinical decisions and reshaping the narrative of colon cancer. However, challenges in standardization and the complex interplay with other factors underscore the need for ongoing research. The chapter delves into CD105's biological functions, shedding light on its intricate role in cancer biology, particularly in angiogenesis and immune evasion. The narrative then explores CD105 expression in normal and cancerous colon tissue, deciphering its correlation with tumor progression stages. A case study approach humanizes the discussion, emphasizing CD105's diverse impact on clinical outcomes. Unveiling CD105's dual dance of angiogenesis and metastasis, the chapter presents a nuanced understanding of its influence in the complex tapestry of colon cancer progression. The ominous impact of CD105 on prognosis, angiogenesis, metastasis, and cellular reprogramming is explored, emphasizing its role as a malevolent force in colon cancer progression. The subsequent sections delve into strategies for targeting CD105 in therapy, providing a comprehensive exploration of monoclonal antibodies, small-molecule inhibitors, anti-adhesion agents, and cytoskeletal disruptors. Case studies and ongoing trials offer glimpses of the potential and challenges in silencing CD105. As the chapter concludes, it reflects on the evolving landscape of colon cancer, acknowledging CD105's potential while urging continued research to unlock its full therapeutic potential.